Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma
- Di Costanzo, Giovan Giuseppe
- de Stefano, Giorgio
- Farella, Nunzia
- Addario, Luigi
- Lampasi, Filippo
- Lanza, Alfonso Galeota
- Imparato, Michele
- TORTORA, RAFFAELLA
- CORDONE, GABRIELLA
- CAPORASO, NICOLA
Publication date
January 2015
DOI Publisher
Future Medicine Ltd ISSN
1479-6694 Citation count (estimate)
9Abstract
Sorafenib is the standard of care in advanced hepatocellular carcinoma. This study was aimed to identify clinical parameters that may predict survival in these patients
Add to ORKG